Formycon AG stock (DE000A1EWVY8): Down 0.4% on Xetra Monday morning

Formycon AG shares fell 0.4% to 18.72 EUR in Xetra trading around 09:28 on May 11, 2026, amid light volume of 1,762 shares traded. The biotech firm focuses on biosimilars for US and global markets.

Formycon AG shares declined 0.4% to 18.72 EUR during Xetra trading at approximately 09:28 local time on May 11, 2026, after opening at 18.46 EUR, according to finanzen.ch as of 05/11/2026. Volume stood at 1,762 shares by that point. The stock is 15.6% above its 52-week low of 15.80 EUR but down significantly from the 52-week high of 31.30 EUR reached on July 29, 2025.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Formycon AG
• Sector/industry: Biotechnology / Biosimilars
• Headquarters/country: Germany
• Core markets: US, Europe
• Key revenue drivers: Biosimilar development and commercialization
• Home exchange/listing venue: Xetra (FSE: FYB)
• Trading currency: EUR

Formycon AG: core business model

Formycon AG develops and markets biosimilars, which are highly similar versions of approved biologic medicines. The company operates from Munich, Germany, and targets treatments in ophthalmology, immunology, and chronic diseases. Its pipeline includes candidates competing with blockbuster drugs, offering potential cost savings for healthcare systems including in the US market.

Formycon focuses on end-to-end biosimilar solutions, from research to commercialization. The firm partners with larger pharmaceutical companies for distribution, enhancing its reach to US investors interested in biotech exposure without direct development risks.

Main revenue and product drivers for Formycon AG

Key products in Formycon's portfolio target high-value biologics. Revenue stems primarily from milestone payments, royalties, and sales through partnerships. Recently, the company noted delays in its annual report publication to April 2026, which contributed to share pressure, per prior coverage on finanzen.ch as of 05/11/2026.

Biosimilars for US markets represent a growth driver, as pricing pressures on originators create opportunities. Formycon's pipeline progress supports long-term revenue potential in this space.

Why Formycon AG matters for US investors

Formycon AG provides US investors access to the European biosimilars boom via its Xetra listing. With biosimilars gaining traction in the US to lower drug costs, Formycon's developments in immunology and ophthalmology align with key healthcare trends. The firm's partnerships extend its footprint into North American markets indirectly.

Industry trends and competitive position

The global biosimilars market is expanding rapidly, driven by patent expirations on biologics. Formycon competes with players like Sandoz and Biocon, differentiating through specialized ophthalmology focus. US approval pathways via FDA add relevance for investors tracking regulatory milestones.

Conclusion

Formycon AG shares showed a modest decline on May 11, 2026, trading at 18.72 EUR amid low volume. The company continues advancing its biosimilars pipeline, with relevance for US healthcare cost trends. Investors monitor upcoming annual results and regulatory updates for further direction. Market conditions and biotech sector dynamics will influence near-term performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.